UCLA Health at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

UCLA Health brings 2 presentations to ENA 2026 in Barcelona. Its program spans immunotherapy and antibody-drug conjugates in the clinic. It reports first-in-human results for AT-1965, a CMTR2 inhibitor and B-cell activating immunotherapy, and covers bispecific antibody-drug conjugates.

OrganizationENA 2026 Attendance
UCLA Health
Los Angeles, CA
Cancer centres & hospitals
Academic health system of the University of California, Los Angeles, providing hospital and cancer care and clinical trials.

Explore the full ENA 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Barcelona. Leave your work email and we’ll be in touch.

Privacy

Download the full ENA 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at UCLA Health

Tell us what you sell and we’ll find the people at UCLA Health most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction